“…These post hoc analyses were performed on data from a Phase III, multicenter, randomized, double-blind, placebo-controlled, forced-withdrawal, parallelgroup, laboratory classroom study of DR/ER-MPH in children (aged 6e12 years) with ADHD. 15 Key inclusion criteria included but were not limited to: diagnosis of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders (5th edition); a baseline ADHD Rating Scale-IV (ADHD-RS-IV) score in at least the 90th percentile normalized for sex and age in at least one of the following categories: inattentive, hyperactive-impulsive, or total score, and a total score 26 at baseline; Clinical Global Impression of Severity (CGI-S) score 4 and Conners' Global IndexeParent (CGI-P) score >10 at baseline; and prior response to MPH therapy or treatment with the same dose of MPH and clinical response with acceptable tolerability for 2 weeks before screening. Key exclusion criteria included but were not limited to: history of or current medical condition or laboratory result that could interfere with study participation, participant safety, or satisfactory completion of the study; any cardiac problems that may place the participant at increased vulnerability to the sympathomimetic effects of a stimulant drug; history of psychosis, bipolar disorder, anorexia nervosa, bulimia, or suicide attempt; and current depression, anxiety, conduct disorder, substance use disorder, or other psychiatric condition that may jeopardize participant safety or interfere with the satisfactory completion of the study.…”